Oncotelic Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a pioneering developer of therapeutic interventions for rare and orphan diseases such as Parkinson’s Disease and various forms of cancer, is thrilled to announce their participation in the BIO International Convention.
The Company’s presentation is readily accessible at https://www.oncotelic.com/wp-content/uploads/2023/05/BIO-2023-V2.pdf
Key points of the presentation include:
- The significant role of TGF-β2 as the primary driver of survival, outpacing the influence of TGF-β1 and TGF-β3.
- The ongoing advancement of clinical trials for OT-101 in conjunction with P201 in Pancreatic Cancer, set to commence in the second half of 2023. Additional combination trials with various checkpoint inhibitors involving multiple cancer types are also slated to begin within the same timeframe.
- The sustained progress towards the IPO of the joint venture, contingent on favorable market conditions.
- The evolution of a state-of-the-art AI-driven nanomedicine platform designed to bolster both internal developmental processes and external collaborative endeavors.
“Our commitment to innovation is reflected in the development of a cutting-edge AI-driven nanomedicine platform. This platform is anticipated to revolutionize the drug development initiatives within both Oncotelic and the joint venture. We are stand ready to invest in our partners supporting their journey from initial concept to clinical trials and through to commercialization,” stated Dr. Vuong Trieu, CEO of Oncotelic and CEO of Sapu.
We extend a warm invitation to all interested parties to explore the details of our presentation and discover more about the future of our groundbreaking work in rare and orphan disease therapeutics.
Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (“AML” through OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on form 10-K/A filed with the SEC on April 19, 2023.